10.1038/s43018-023-00578-z - Interim survival analysis of the rand...

This document has been corrected

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

10.1038/s43018-023-00578-z

Published Online: 2023-06-15

Journal: Nature Cancer•Publisher: Springer Science and Business Media LLC

Authors: Caicun Zhou•Changli Wang•Chunhong Hu•Chunling Liu•Hao Wang•Hong Shen•Hui Zhao•Jason Yang•Jianhua Chen•Jianying Zhou•Jingru Wang•Jingzhang Li•Jiuwei Cui•Jiwei Liu•Kangsheng Gu•Lejie Cao•Meili Sun•Mengmeng Qin•Mengzhao Wang•Ping Sun•Rong Wu•Rumei Chen•Si Sun•Wenxiu Yao•Wu Zhuang•Xingya Li•Xueqin Chen•Yan Yu•Yiping Zhang•Yongqian Shu•You Lu•Yunpeng Liu•Zhiyong Ma•Ziping Wang

This document has been corrected

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

10.1038/s43018-023-00578-z

Published Online: 2023-06-15

Journal: Nature Cancer

NOW

2024-01-05•Correction

Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

10.1038/s43018-023-00719-4

* information provided by CrossRef

2024-01-05•Correction

10.1038/s43018-023-00719-4

* information provided by CrossRef

2023-06-15•Published

2024-01-05•Correction

Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

10.1038/s43018-023-00719-4

* information provided by CrossRef

This document has been corrected

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

10.1038/s43018-023-00578-z

Published Online: 2023-06-15

Journal: Nature Cancer•Publisher: Springer Science and Business Media LLC